Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NRXP
- Price
- 1.80
- Stock movement up
- +- (0.00%)
- Company name
- NRX Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 53.29M
- Ent value
- 86.86M
- Price/Sales
- 213.16
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 13.85
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -38.78%
- 3 year return (CAGR)
- -45.79%
- 5 year return (CAGR)
- -65.95%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NRXP does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 213.16 |
| Price to Book | - |
| EV to Sales | 347.43 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.61M |
| EPS (TTM) | -1.71 |
| FCF per share (TTM) | -0.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 250.00K |
| Gross profit (TTM) | 146.00K |
| Operating income (TTM) | -15.23M |
| Net income (TTM) | -38.06M |
| EPS (TTM) | -1.71 |
| EPS (1y forward) | 0.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 58.40% |
| Operating margin (TTM) | -6094.00% |
| Profit margin (TTM) | -15224.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.18M |
| Net receivables | 239.00K |
| Total current assets | 11.95M |
| Goodwill | 610.00K |
| Intangible assets | 1.78M |
| Property, plant and equipment | 419.00K |
| Total assets | 15.00M |
| Accounts payable | 4.26M |
| Short/Current long term debt | 347.00K |
| Total current liabilities | 40.59M |
| Total liabilities | 40.75M |
| Shareholder's equity | -25.75M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.50M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -12.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -253.81% |
| Return on Invested Capital | 148.87% |
| Cash Return on Invested Capital | 48.88% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.80 |
| Daily high | 1.85 |
| Daily low | 1.73 |
| Daily Volume | 478K |
| All-time high | 627.10 |
| 1y analyst estimate | 36.75 |
| Beta | 1.96 |
| EPS (TTM) | -1.71 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NRXP | S&P500 | |
| Current price drop from All-time high | -99.71% | -1.82% |
| Highest price drop | -99.81% | -56.47% |
| Date of highest drop | 14 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -58.86% | -10.84% |
| Avg time to new high | 13 days | 12 days |
| Max time to new high | 1266 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
53.29M
Marketcap category
Small-cap
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page